FindTrial
Sign In

A randomised placebo-controlled trial of epirubicin and quinidine in patients with advanced breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN23196537
Enrollment
Unknown
Registered
2001-07-01
Start date
1988-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Breast

Interventions

Both arms receive Epirubicin 100 mg/m^2 iv every 3 weeks for a maximum of eight doses. At each cycle patients also receive a 6-day course of capsules either Quinidine 250 mg or placebo.

Sponsors

Cancer Research UK (CRUK) (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Histologically proven metastatic or locally advanced disease 2. Measurable or evaluable disease 3. World Health Organisation (WHO) Performance status at least 2 4. Haemoglobin =10 g% 5. White Blood Count (WBC) >4.0 x10^9/l 6. Platelets =100 x 10^9/l 7. Bilirubin within normal range 8. Not currently receiving hormone treatment 9. No prior chemotherapy for advanced disease

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026